Ameriprise
CLYM

Ameriprise’s Climb Bio CLYM Stock Holding History

Ameriprise’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-139,529
Closed -$558K – 4245
2025
Q4 		$558K Buy
+139,529
New +$335K ﹤0.01% 3581

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ameriprise's CLYM Position: Q1 2026 in Review

Ameriprise sold out of Climb Bio (CLYM) in Q1 2026, closing a stake of 139,529 shares — an estimated $558K sold.

Ameriprise first reported a position in CLYM in Q4 2025 and held it in 1 quarter. The position peaked at $558K in Q4 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Ameriprise reported no remaining Climb Bio position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 139,529 Climb Bio shares in Q1 2026, an estimated $558K.
  • Ameriprise first reported a position in Climb Bio in Q4 2025 and held it in 1 quarter.
  • Ameriprise's Climb Bio position peaked at $558K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.